Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Stockholm, Sweden and Watertown, Mass. July 28, 2020 - Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) today announced that the strategic licensing agreement with Selecta Biosciences, Inc. (Nasdaq: SELB) for SEL-212, entered into as earlier announced on 11 June 2020, became effective on 28 July following the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period. Under the licensing agreement Sobi must pay USD 75 million in cash as an upfront license fee within 45 days of the effective date. In addition,